Bayer (FRA:BAYN) has been assigned a €72.00 ($83.72) target price by stock analysts at Societe Generale in a note issued to investors on Thursday. The firm currently has a “neutral” rating on the healthcare company’s stock. Societe Generale’s price objective indicates a potential upside of 13.51% from the company’s previous close.
Other equities analysts have also issued reports about the company. UBS Group set a €130.00 ($151.16) target price on Bayer and gave the stock a “buy” rating in a research report on Friday, August 17th. Baader Bank set a €123.00 ($143.02) target price on Bayer and gave the stock a “buy” rating in a research report on Wednesday, August 22nd. Sanford C. Bernstein set a €115.00 ($133.72) target price on Bayer and gave the stock a “buy” rating in a research report on Wednesday, September 5th. Kepler Capital Markets set a €84.00 ($97.67) target price on Bayer and gave the stock a “buy” rating in a research report on Monday, September 24th. Finally, Barclays set a €100.00 ($116.28) price target on Bayer and gave the company a “buy” rating in a research report on Tuesday, October 9th. Six equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Bayer currently has a consensus rating of “Buy” and a consensus target price of €90.80 ($105.58).
Shares of FRA:BAYN opened at €63.43 ($73.76) on Thursday. Bayer has a twelve month low of €91.58 ($106.49) and a twelve month high of €123.82 ($143.98).
Bayer Company Profile
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Read More: Market Capitalization
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.